Core Insights - EssilorLuxottica reported consolidated revenue of €6.87 billion ($8.03 billion) for Q3 2025, reflecting an 11.7% increase at constant exchange rates compared to Q3 2024, and a 6.7% increase at current exchange rates [1][6] Revenue Performance - Revenue growth was observed across all regions and channels, driven by demand in wearables, vision care, and sunglasses [1] - Vision care and sunglasses sales rose by 5% at constant exchange rates, while wearables significantly contributed to overall results due to product development [2] - Professional solutions revenue increased by 11.9% to €3.22 billion, and direct-to-consumer revenue rose by 11.6% to €3.64 billion [2] Regional Performance - North America reported revenue of €2.99 billion, up 12.1% at constant exchange rates [2] - EMEA revenue increased by 12.7% to €2.69 billion, and Asia-Pacific revenue rose by 10.5% to €822 million, while Latin America grew by 5.2% to €355 million, all at constant exchange rates [3] Product Development and Innovations - The company highlighted the continued uptake of its AI-glasses range and growth in myopia management solutions [3] - EssilorLuxottica's Stellest lens received FDA approval and will be available to US eyecare professionals starting Q4 2025 [3] Strategic Acquisitions and Outlook - Recent strategic acquisitions include the closing of Optegra and the announced acquisition of RetinAI [4] - The company maintains a long-term outlook of mid-single-digit annual revenue growth between 2022 and 2026 at constant exchange rates, targeting total revenue between €27 billion and €28 billion, with an adjusted operating profit margin of 19% to 20% by the end of the period [4] Management Commentary - The chairman and CEO, Francesco Milleri, and deputy CEO, Paul du Saillant, emphasized the achievement of the best quarter since the group's creation, highlighting the strength of their vision and management [5] - They noted that the results were fueled by contributions from EMEA and North America, along with strong momentum in wearables and vision care [6]